Unfortunately, only marginal benefit was observed in early clinical trials with vessel-inhibiting therapies for advanced NSCLC, where the focus was mainly on the repression of vessel sprouting by inhibition of VEGF signalling [50]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.